Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gleave

Showing results (591-600 of 839) with videos related to

Pageof 84
Sort By:
Nature Communications|October 6, 2018
Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancersYan Zhang, Dayong Zheng, Ting Zhou, et al.
European Urology Oncology|May 22, 2021
Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)Michael J Morris, Jose Mauricio Mota, Kristine Lacuna, et al.
Molecular and Cellular Biology|December 24, 2008
PTEN loss promotes mitochondrially dependent type II Fas-induced apoptosis via PEA-15James W Peacock, Jodie Palmer, Dieter Fink, et al.
European Urology Oncology|May 31, 2022
First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the LiteratureAdam B Weiner, Aisha L Siebert, Sarah E Fenton, et al.
Nature Communications|March 22, 2021
A noncanonical AR addiction drives enzalutamide resistance in prostate cancerYundong He, Ting Wei, Zhenqing Ye, et al.
Journal of Clinical Pathology|January 30, 2007
Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancersAshish B Rajput, Melinda A Miller, Alessandro De Luca, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 25, 2024
USP11 promotes prostate cancer progression by up-regulating AR and c-Myc activityMajid Pornour, Hee-Young Jeon, Hyunju Ryu, et al.
Cell Death & Disease|October 30, 2015
DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosisJ Zhou, Z Ning, B Wang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 15, 2022
DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancerThi Khanh Le, Chaïma Cherif, Kenneth Omabe, et al.
Nucleic Acids Research|February 2, 2023
SMAD3 promotes expression and activity of the androgen receptor in prostate cancerHee-Young Jeon, Majid Pornour, Hyunju Ryu, et al.
Pageof 84

Showing results (591-600 of 839) with videos related to

Sort By:
Pageof 84
Nature Communications|October 6, 2018
Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancersYan Zhang, Dayong Zheng, Ting Zhou, et al.
European Urology Oncology|May 22, 2021
Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)Michael J Morris, Jose Mauricio Mota, Kristine Lacuna, et al.
Molecular and Cellular Biology|December 24, 2008
PTEN loss promotes mitochondrially dependent type II Fas-induced apoptosis via PEA-15James W Peacock, Jodie Palmer, Dieter Fink, et al.
European Urology Oncology|May 31, 2022
First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the LiteratureAdam B Weiner, Aisha L Siebert, Sarah E Fenton, et al.
Nature Communications|March 22, 2021
A noncanonical AR addiction drives enzalutamide resistance in prostate cancerYundong He, Ting Wei, Zhenqing Ye, et al.
Journal of Clinical Pathology|January 30, 2007
Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancersAshish B Rajput, Melinda A Miller, Alessandro De Luca, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 25, 2024
USP11 promotes prostate cancer progression by up-regulating AR and c-Myc activityMajid Pornour, Hee-Young Jeon, Hyunju Ryu, et al.
Cell Death & Disease|October 30, 2015
DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosisJ Zhou, Z Ning, B Wang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 15, 2022
DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancerThi Khanh Le, Chaïma Cherif, Kenneth Omabe, et al.
Nucleic Acids Research|February 2, 2023
SMAD3 promotes expression and activity of the androgen receptor in prostate cancerHee-Young Jeon, Majid Pornour, Hyunju Ryu, et al.
Pageof 84